Current Treatment Options for Patients with Myotonic Dystrophy Type 2

Abstract Purpose of the review Myotonic dystrophy types 1 and 2 are frequent forms muscular dystrophies in adulthood. Their clinical differences need to be taken into account for most appropriate treatment patients. The aim this article is provide an overview on current upcoming therapeutic options patients with myotonic type (DM2). Recent findings At moment, no disease-modifying therapies available DM2; next-generation may however near future. In meanwhile, symptomatic management has greatly improved, thank production consensus-based standards care growing evidence efficacy anti-myotonic drugs, promising employment cannabinoids symptom’s relief, regular monitoring, early detection treatable extra-muscular manifestations. Summary DM2 currently relies coordinated intervention a multidisciplinary team. It remains determined whether causal will applicable also DM2.